Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT‑2 pancreatic cancer mouse model-Reference-Cited by-同舟云学术

Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT‑2 pancreatic cancer mouse model

Published:2017-12-29 Issue: Volume: Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Higuchi Tamami¹,Yokobori Takehiko²^ORCID,Naito Tomoharu³,Kakinuma Chihaya³,Hagiwara Shinji³,Nishiyama Masahiko¹,Asao Takayuki⁴

Affiliation:

1. Department of Molecular Pharmacology and Oncology, Gunma University, Graduate School of Medicine, Maebashi, Gunma 371‑8511, Japan

2. Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma 371‑8511, Japan

3. Pharmaceutical and Healthcare Research Laboratories, Research and Development Management Headquarters, Fujifilm Corporation, Kaisei‑machi, Kanagawa 258‑8577, Japan

4. Big Data Center for Integrative Analysis, Gunma University Initiative for Advanced Research (GIAR), Maebashi, Gunma 371‑8511, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orthotopic and metastatic tumour models in preclinical cancer research;Pharmacology & Therapeutics;2024-05

2. m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway;Journal of Experimental & Clinical Cancer Research;2023-08-22

3. Stress exacerbates pancreatic cancer both directly and indirectly by creating an immunosuppressive environment;Journal of Hepato-Biliary-Pancreatic Sciences;2022-12-13

4. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma;Journal of Translational Medicine;2022-10-05

5. Research progress in the establishment of pancreatic cancer models and preclinical applications;Cancer Innovation;2022-10